<http://schema.org/description>
"Lexicon Pharmaceuticals (NAS: LXRX) has an important year ahead. The small-cap biotech will have two drugs in late-stage trials, the final step before a run at approval from the Food and Drug"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.aol.com/article/2012/12/05/3-things-to-watch-at-lexicon/20395134/?gen=1>